Gilead's Truvada faces a tough audience for HIV-prevention use

About a year and a half ago, the FDA approved the Gilead Sciences ($GILD) pill Truvada to prevent HIV infection in high-risk patients. But demand has been slow to build, The New York Times reports. Some doctors are skeptical, and some men fear the stigma of using an HIV-prevention pill. Plus, younger generations of gay men aren't as fearful of HIV as older men are, the Times says. Report (sub. req.)

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.